Table 1.
Baseline Characteristics
| Variable | All (n=1,843) | Yonsei University (n=804, 43.6%) | Cha University (n=1039, 56.4%) | p-value |
|---|---|---|---|---|
| Demographic | ||||
| Age, yr | 49.4±11.4 | 52.4±10.7 | 47.1±11.3 | <0.001 |
| Male sex | 1,063 (57.7) | 443 (55.1) | 620 (59.7) | 0.051 |
| Diabetes mellitus | 206 (11.2) | 44 (5.5) | 162 (15.6) | <0.001 |
| Cirrhosis | 617 (33.5) | 379 (47.1) | 238 (22.9) | <0.001 |
| Laboratory | ||||
| α-Fetoprotein, ng/mL | 6.1±22.4 | 5.7±21.5 | 6.3±23.1 | 0.579 |
| HBeAg positivity | 453 (24.6) | 154 (19.2) | 299 (28.8) | <0.001 |
| HBV DNA, log IU/mL | 2.8±2.1 | 2.7±2.0 | 2.9±2.2 | 0.021 |
| Aspartate aminotransferase, IU/L | 37.3±57.6 | 33.7±43.7 | 40.1±66.4 | 0.013 |
| Alanine aminotransferase, IU/L | 44.4±90.5 | 39.2±70.1 | 48.5±103.5 | 0.022 |
| Serum albumin, g/dL | 4.4±0.4 | 4.3±0.3 | 4.5±0.4 | <0.001 |
| Total bilirubin, mg/dL | 0.8±0.5 | 0.9±0.5 | 0.8±0.4 | <0.001 |
| Platelet count, 109/L | 174±60 | 168±64 | 178±57 | <0.001 |
| Ongoing antiviral therapy | 645 (35.0) | 278 (34.6) | 367 (35.3) | 0.768 |
Data are presented as mean±SD or number (%). HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.